Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study.

Abstract

A subgroup of patients with PSE resulting from chronic liver disease may benefit from the administration of flumazenil.